karyotype contained a del(5q) abnormality; the underlying mechanism of megakaryocytic proliferation in these cases and their relationship to the entity MDS with 5qÀ remains unknown.
Approximately 45% of patients with de novo acute myeloid leukemia (AML) have a normal karyotype (nk-AML). 1 The complete remission (CR) rates for this group are around 80% with 5 years survival of 40-50%. The molecular heterogeneity of nk-AML has been recently described and may relate to prognostic stratification and new therapeutic approaches. 2 Recently, Falini et al. 3 reported a high incidence of heterozygous mutations in the gene coding for nucleophosmin (NPM), particularly in nk-AML. All mutations are located in exon 12 and are predicted to alter the protein structure at its C-terminal, causing delocalization of NPM from its normal nucleolar stores to the cytoplasm. Since this initial publication, six reports have investigated the prognostic value of NPM mutations in AML and consistently report better event-free survival (EFS) and overall survival (OS) in patients with mutated NPM (NPMm). 4, 5 However, the good prognostic impact of NPM mutations may be hampered by its association to internal duplication of FLT3 (FLT3-ITD) mutations, which generally correlate with a worse outcome. Indeed, the favorable impact of NPM mutations on OS and EFS was detected only in the NPMm/FLT3-ITD À subgroup of patients. Here, we analyzed the clinical spectrum and prognostic value of NPM mutations in 110 patients with de novo nk-AML.
Detection of NPM gene mutations was carried out on genomic DNA by polymerase chain reaction and genescan analysis. NPM mutations were detected in 46% of patients. In 27 patients analyzed by immunofluorescence staining for NPM localization, a 100% correlation with the NPM mutational status was observed. NPM mutations were significantly correlated with female gender (P ¼ 0.02) and CD34 expression (P ¼ 0.001) ( Table 1 ). There was no statistical difference between NPMm and NPM wild-type (NPMwt) patients when considering the age, French-American-British classification subgroups, white blood cell (WBC) count, FLT3-ITD mutation, bone marrow blasts infiltration and myelodysplastic syndrome-related features. FLT3-ITD mutations were determined in 107 patients. There was no significant difference between the NPMm and NPMwt patients for the presence of FLT3-ITD mutations (NPMm, 37.5%; NPMwt, 28.8%; P ¼ 0.34). All patients were treated by induction chemotherapy combining daunorubicin or idarubicin and aracytin. Patients under 60 years (n ¼ 75) with human lymphocyte antigen (HLA)-identical sibling were allocated to allogeneic stem cell transplantation (allo-SCT) in first CR, others to autologous SCT (ASCT) or intensive chemotherapy with highdose aracytin. The median time of follow-up was 3 years. The CR rate was similar in the two groups (NPMm: 84%; NPMwt: 83.3%, P ¼ 0.93). Although there is a trend to a higher plateau for EFS, relapse-free survival (RFS) and OS in NPMm patients (medians not reached), the differences were not statistically significant between NPMm and NPMwt groups, probably owing to the small number of patients analyzed (Figure 1 ). Only age (450 years), but not gender, WBC, CD34 expression or FLT3-ITD mutations, was significantly associated with lower EFS and OS. Even if there was no statistical association of FLT3-ITD mutations to NPM mutations, we determined the survival data of the four groups of patients using a Cox proportional hazards regression model:
No prognostic effect on OS and EFS was detected for both variables. As expected, the OS and EFS were not different for the NPMm/FLT3-ITD À group as compared to others (P ¼ 0.42 and P ¼ 0.25, respectively).
Dö hner et al. 6 recently reported that allo-SCT did not improve the outcome of NPMm/FLT3-ITD À patients. In our cohort, we thought to determine if allo-SCT influenced the prognostic effect of NPM mutations in patients younger than 60 (n ¼ 75). In the NPMm/non-allografted group, 13/27 patients (48%) were FLT3-ITD þ , whereas 4/16 patients (25%) were FLT3-ITD þ in the NPMwt/non-allografted group. The median follow-up for Kaplan-Meier OS curves according to NPM mutations and allo-SCT for AML patients under 60 years.
Letters to the Editor these patients is 3.6 years. Figure 2 shows OS curves of NPMm/ allografted (n ¼ 7), NPMm/non-allografted (n ¼ 27), NPMwt/ allografted (n ¼ 25) and NPMwt/non-allografted (n ¼ 16) patients. NPM status had a prognostic effect only in nonallografted patients (median not reached for NPMm, 24.4 months for NPMwt; P ¼ 0.04). Indeed, the NPMwt/non-allografted patients had a very poor 3 years OS compared to the other patients (P ¼ 0.02). By contrast, NPMm/non-allografted patients showed a 3-year OS probability of 75%.
A major issue in nk-AML is to determine robust prognosis factors because of the marked heterogeneity in outcome. Despite this heterogeneity, most patients with an HLAmatched sibling are allocated to allo-SCT in first CR. However, a substantial proportion of patients may be cured with less toxic procedures such as ASCT or chemotherapy. Interestingly, Dö hner et al. 6 reported that allo-SCT did not improve the outcome of NPMm/FLT3-ITD À patients. In our series, NPMm/non-allografted patients did particularly well. Furthermore, we found that allo-SCT had a favorable impact only in the NPMwt patients. Indeed, the OS of the NPMwt patients who were not allografted was particularly poor. Although retrospective, these results suggest that the NPM status may define subgroups with risk-adapted therapy. If confirmed by large prospective studies, they should raise the question whether allo-SCT should be used only for the NPMwt patients.
